MicroRNAs biomarkers profiling in diagnosis and therapeutic management of hepatitis B virus infection

Introduction: Due to lack of unique method with high accurate and repeatable, assessment and even treatment of HBV infection and it,s complications such as cirrhosis and HCC has been with limitations. MicroRNAs (miRNAs) are small 19-24 nucleotide-long molecules with up-regulated and down-regulated Expression.The present research provides a narrative review expression profiling biomarkers miRNAs in diagnosis, treatment and differnciated CHB from cirrhosis or HCC. Methods: We search database google scholar, pubmed, scopus, SID on English Languish article and also assess EASL and AASLD (2002-2016). Results: Some of miRNAs are specifically more abundant in specific tissues, such as miR-122 in the liver. MiRNAs such as miRNA125a, miRNA141, miRNA1, miRNA197, miRNA122 and miRNA372, 373 have a major role in CBH and miRNA29a/b/c, miRNA200, miRNA199, miRNA133a, miRNA214 andmiRNA181b have a major role in fibrosis/cirrhosis. miR-106b and miR-181b, have a significant clinical diagnostic value in liver cirrhosis, especially at its early stages. miR-122, miR-192, miR-92, miR-223, miR-26a, miR-27a and miR-801, has a highly accurate diagnostic power that can differentiate HCC from CHB and cirrhosis and from healthy people as well as. Conclusion: In the future, the miRNAs biomarkers provide researchers with a golden opportunity and can be used as early diagnostic and miRNAs based-therapeutic panels and current knowledge between miRNAs profiling biomarkers and progressive stage of HBV related diseases. Panels of miRNAs will play a significant role in decision-making about their proper course in both of treatment and diagnosis of diseases such as hepatitis B virus infection. Abrrevation: hepatitis B virus (HBV(,MicroRNAs (miRNAs), chronic hepatitis B (CHB), hepatocellular carcinoma (HCC), European Association for the Study of Liver (EASL) and American Association for Study of Liver (AASLD)